TURKU, FI / ACCESS Newswire / July 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2026.
The Options have been allocated under the Share Option Plan 2026 and are exercisable after 1 June 2029, vesting 100%. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share based on the resolution of the Annual General Meeting on 4 May 2026 and € 0.53 for the recipients of options who are US nationals. The terms of the Share Option Plan 2026 are available on the Company's website.
The granted 2,173,000 Options entitle the option holders to subscribe for a total of 2,173,000 new ordinary shares in the Company, if exercised in full, and represent 0.95 % of the fully diluted ordinary share capital of the Company on the grant date.
Included in the number of Options granted are the following Options which were issued to directors and other persons discharging managerial responsibilities ("PDMRs"):
Director | Options granted |
|
|
Colin Bond | 60,000 |
Christine Roth | 60,000 |
George Golumbeski | 60,000 |
Juho Jalkanen | 220,000 |
Marie-Louise Fjällskog | 60,000 |
Tuomo Pätsi | 200,000 |
Total directors | 660,000 |
Other PDMR |
|
Maija Hollmén | 38,000 |
Vesa Karvonen | 120,000 |
Jurriaan Dekkers | 170,000 |
Petri Bono | 170,000 |
Ralph Hughes | 120,000 |
Kaisa Kyttä | 100,000 |
Joab Wiliamson | 100,000 |
Total other PDMRs | 818,000 |
|
|
Total Company personnel | 695,000 |
For more information, please contact:
IR Partners, Finland |
|
FINN Partners, US | +1 847 791-8085 |
Cairn Financial Advisers LLP | +44 (0) 207 213 0880 |
Sisu Partners Oy | +358 (0)40 555 4727 |
About BEXMAB
The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
| ||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated |
| |||||||
a. | Name | a. Colin Bond |
| ||||||
2 | Reason for notification |
|
| ||||||
a. | Position/Status | Person discharging managerial responsibilities/person closely associated |
| ||||||
b. | Initial notification/ | Initial notification |
| ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| |||||||
a. | Name | Faron Pharmaceuticals Oy |
| ||||||
b. | LEI | 7437009H31TO1DC0EB42 |
| ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| |||||||
a. | Description of the financial instrument, type of instrument | Options over new ordinary shares |
| ||||||
b. | Nature of the transaction | Grant of options made under the Faron Share Option Plan 2026. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share and € 0.53 for the recipients of options who are US nationals. |
| ||||||
c. | Price(s) and volume(s) |
|
|
|
|
| |||
| Price(s) | Volume(s) |
| ||||||
a. € 0.50 | 60,000 |
| |||||||
| |||||||||
d. | Aggregated information |
|
| ||||||
e. | Date of the transaction |
|
| ||||||
f. | Place of the transaction | Turku |
| ||||||
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
